watch
Advanced Cell Technology, Inc.

Advanced Cell Technology, Inc.

Sector: Commercial Physical And Biological Research Region: MA, United States


: | OTC Markets: ACTC.OB


Advanced Cell Technology, Inc., ("ACT" OTCBB: ACTC) is a biotechnology company that specializes in the development of cellular therapies for the treatment of diseases and conditions that impact tens of millions of people worldwide. The company applies stem cell-based technologies (both for adult and "embryo-safe" human embryonic stem cells) and other proprietary methods in the field of regenerative medicine to bring patient-specific therapies from the lab bench to the bedside.

Latest Media

Warning! Third-party cookies must be enabled to view SlideShare presentations. ×

Having trouble?

2014 BIO CEO Corporate Presentation 

Advanced Cell Technology, Inc. video

2014 BIO CEO Corporate Presentation 

Advanced Cell Technology, Inc. video

Company Presentation - Advanced Cell Technology (ACT)

Advanced Cell Technology, Inc. video

World Stem Cells & Regenerative Medicine Congress

Advanced Cell Technology, Inc. video

ARM's Regen Med investor Day

Advanced Cell Technology, Inc. video

BIO-Europe, Barcelona, Spain

Advanced Cell Technology, Inc. video

Biotech Showcase

Executives

Ted Myles, Interim President, CFO and Executive Vice President of Corporate Development
Ted Myles joined ACT in June 2013, as the company’s Chief Financial Officer and Executive Vice President of Corporate Development. From November 2008 to June 2013 Mr. Myles was with PrimeraDx, a privately-held molecular diagnostics company, where he served as Chief Financial Officer and Vice President of Operations. At PrimeraDx, Mr. Myles helped to lead the company from the proof-of-concept stage to become a fully integrated commercial organization. Prior to joining PrimeraDx, Mr. Myles was the Chief Financial Officer and Senior Vice President of Finance at Pressure BioSciences, a Nasdaq-listed, life-science tools company. Earlier in his career, Mr. Myles held financial positions of increasing responsibility with EMD Pharmaceuticals (a subsidiary of Merck KGaA), SG Cowen Securities Corporation, Boston Biomedica and PriceWaterhouseCoopers.

He received a master’s degree in business administration, with an emphasis on strategy and corporate finance, from Washington University in St. Louis and a bachelor’s degree in business administration from the University of Hartford. Mr. Myles became a CPA in 1996.
Robert Lanza, M.D. - Chief Scientific Officer
Dr. Robert Lanza joined ACT in 1999 and has over 30 years of research and industrial experience in the area of stem cells and regenerative medicine. He is currently an Adjunct Professor at the Institute for Regenerative Medicine at Wake Forest University School of Medicine. He has several hundred of publications and inventions, and over two dozen scientific books: among them, “Essentials of Stem Cell Biology” and “Principles of Tissue Engineering” which are recognized as the definitive references in the field. Others include “Principles of Regenerative Medicine” and “One World: The Health & Survival of the Human Species in the 21st Century” (as editor, with forewords by C. Everett Koop and former President Jimmy Carter).

He is a former Fulbright Scholar and studied as a student in the laboratories of Richard Hynes (MIT), Jonas Salk (The Salk Institute) and Nobel laureates Gerald Edelman (Rockefeller University) and Rodney Porter (Oxford University). He also worked closely (and co-authored a series of papers) with the late Harvard psychologist B.F. Skinner and heart transplant pioneer Christiaan Barnard. Dr. Lanza received his B.A. and M.D. degrees from the University of Pennsylvania, where he was both a University Scholar and Benjamin Franklin Scholar. He has received numerous awards, including an NIH Director’s Award (2010) for “Translating Basic Science Discoveries into New and Better Treatments”; the 2010 “Movers and Shakers” Who Will Shape Biotech Over the Next 20 Years (BioWorld, along with Craig Venter and President Barack Obama); the 2005 Rave Award for Medicine (Wired magazine, “For eye-opening work on embryonic stem cells”) and the 2013 "Top 50 Global Stem Cell Influencers" from Terrapinn (Dr. Lanza was among the top four, alongside James Thomson and Nobel laureate Shinya Yamanaka).
Dr. Eddy Anglade, Executive Vice President of Clinical Development
Dr. Eddy Anglade joined ACT in January 2014 as the Company's Executive Vice President of Clinical Development. From 2006 until 2013, Dr. Anglade was Chief Medical Officer and Co-founder of Lux Biosciences, Inc., a privately held development stage biotechnology company whose therapeutic focus included ophthalmic diseases with high and unmet medical needs, including non-infectious posterior uveitis, high risk corneal transplantation and dry eye disease. As Chief Medical Officer at Lux, his responsibilities included leadership of clinical development, regulatory strategy and safety for all of its clinical programs. Prior to joining Lux Biosciences, Dr. Anglade was Vice President of Clinical Development at Enzon Pharmaceuticals, Inc. with responsibility for clinical development of its oncology and immunology portfolio. He started his career in the pharmaceutical industry at Hoffmann-LaRoche, Inc. as a Medical Director in its Transplantation and Virology Specialty Care franchises.

Dr. Anglade completed his ophthalmology residency at the Massachusetts Eye and Ear Infirmary/Harvard Medical School with further specialty training in ocular inflammation at the National Eye Institute/National Institutes of Health and received his medical degree from the Yale University School of Medicine. He received his AB at Columbia University.
Roger Gay, Ph.D., Senior Director of Manufacturing
For the past 29 years, Dr. Roger Gay has been involved in clinical manufacturing and product development at a number of biotechnology companies specializing in cell-based products and services, including Organogenesis, Diacrin, Genvec and Mytogen (which was later acquired by ACT). He has extensive experience directing and leading product development and clinical trial manufacturing for cellular products, having planned and executed R&D programs leading to market introduction of first-ever products for two biotechnology companies prior to joining ACT. Dr. Gay holds a Ph.D. in biochemistry from the University of Rochester and was a post-doctoral fellow at Harvard Medical School.
Matthew Vincent, Ph.D., Director of Business Development
Matt Vincent joined ACT in 2011 as Director of Corporate Development, having worked as outside intellectual property (IP) counsel and then as a business development consultant with the company since 2005. Dr. Vincent has 21 years of relevant experience in the life sciences industry, ranging from intellectual property strategy and patent litigation, to strategic partnering and collaborations, to regulatory affairs and clinical trial management. Dr. Vincent holds a B.S. in Chemistry from Worcester Polytechnic Institute, a Ph.D. in Biochemistry from Tufts University School of Medicine and a J.D. from Suffolk University School of Law. He holds several patents and has co-founded a number of life science companies, two of which have FDA-approved products or are currently in human clinical trials.

News & Analysis